Navigation Links
Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

Absorbable Stent Continues to Show Promise as Future-Generation Technology

BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Abbott today announced positive results from ABSORB, the world's first clinical trial evaluating the safety and performance of a fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease. Nine-month results from the first 30 patients in the trial, presented today at the EuroPCR meeting, demonstrated no stent thrombosis and a low (4.0 percent, one patient) rate of Major Adverse Cardiac Events (MACE), such as heart attack or repeat interventional medical treatment. The results confirm the six-month findings from ABSORB, which were announced in March 2007, and show no new adverse events between six and nine months.

"These ABSORB nine-month data reaffirm the positive results we saw with Abbott's bioabsorbable stent system at six months," said ABSORB investigator Dariusz Dudek, M.D., Jagiellonian University in Krakow, Poland. "As we continue the ABSORB trial, we look forward to evaluating an updated version of the stent system designed to deliver additional support to the arterial wall and with the potential to reduce late lumen loss (vessel renarrowing) even further."

Abbott's everolimus eluting bioabsorbable stent is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbott's bioabsorbable stent is designed to restore blood flow by propping a clogged vessel open, and provide support until the blood vessel heals. Unlike a metallic stent however, a bioabsorbable stent is designed to be slowly metabolized by the body and completely absorbed over time.

At the EuroPCR meeting, Abbott will unveil an updated, bioabsorbable stent design that will be used in the next cohort of patients enrolled in the ABSORB trial. The new stent features
'"/>




Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2
... MabVax Therapeutics Inc., a privately held clinical stage ... based therapies to address the unmet medical need of preventing ... in a Phase II clinical trial aimed at assessing the ... the recurrence of sarcoma. The clinical trial will enroll 126 ...
... NEW YORK , July 22 Reportlinker.com announces that a new market ... , , ... , http://www.reportlinker.com/p0240598/Wireless-Medical-Technologies-2007-2010.html ... Wireless Medical Technologies work on the basis of ...
Cached Medicine Technology:MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma 2MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma 3Reportlinker Adds Wireless Medical Technologies 2007-2010 2Reportlinker Adds Wireless Medical Technologies 2007-2010 3Reportlinker Adds Wireless Medical Technologies 2007-2010 4
(Date:4/23/2014)... developed a way to detect and measure cancer levels ... with tails of synthetic DNA., A team led by ... gold nanoparticles to target and bind to fragments of ... which can indicate the presence and stage of breast ... a cell can be determined by examining the specific ...
(Date:4/23/2014)... an important brain receptor has a dramatic effect against ... a University at Buffalo animal study has found. , ... a novel lead compound for treating cocaine addiction, for ... published as an online preview article in Neuropsychopharmacology ... RO5263397, severely blunted a broad range of cocaine addiction ...
(Date:4/23/2014)... April 23, 2014Men whose testosterone falls below normal levels ... be overweight and have heart disease and type 2 ... testosterone-deficient men for further testing and possible treatment is ... Health , a peer-reviewed publication from Mary Ann Liebert, ... Journal of Men,s Health website at ...
(Date:4/23/2014)... accessible detection methods that can rapidly screen a ... single cell inside that population has been seriously ... , In the Royal Society of Chemistry journal ... he and his coworkers have developed a novel ... protein ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... , , , MOUNTAIN VIEW, Calif., July ... system solutions to acute healthcare facilities, today announced results for its second quarter ... results: Revenue for the second quarter of 2009 was $52.6 million, up ... million or 16.9% from the second quarter of 2008. , ...
... , LANCASTER, Pa., July 23 Eastern Insurance Holdings, ... to release financial results for the second quarter ended June 30, ... 2009. , , EIHI will ... a.m. ET to review the Company,s 2009 second quarter results. The ...
... in production is hampering efforts, but a nasal spray version ... million: that,s the number of doses of injectable swine flu ... October, with more doses coming in the form of a ... each person getting two doses spread a month apart, the ...
... , , PITTSBURGH, July 23 ... stopping in Pennsylvania throughout the week of July 27-31 at ... access information on programs that provide prescription medicines for free ... 8.2 percent -- compared to 5.1% a year ago -- ...
... dogma has been that bone-forming cells, derived from the body,s ... skeleton. However, new research shows that specialized cells in the ... from the bone marrow and that these bloodstream cells are ... skeleton. This work, published online this month in the journal ...
... , , NORTH BERGEN, N.J., July ... Industries Inc., today announced that it has filed a registration statement on ... proposed initial public offering of its common stock. Upon consummation of ... shares of common stock to be sold in the offering are expected ...
Cached Medicine News:Health News:Omnicell Announces Second Quarter 2009 Results 2Health News:Omnicell Announces Second Quarter 2009 Results 3Health News:Omnicell Announces Second Quarter 2009 Results 4Health News:Omnicell Announces Second Quarter 2009 Results 5Health News:Omnicell Announces Second Quarter 2009 Results 6Health News:Omnicell Announces Second Quarter 2009 Results 7Health News:Omnicell Announces Second Quarter 2009 Results 8Health News:Omnicell Announces Second Quarter 2009 Results 9Health News:Omnicell Announces Second Quarter 2009 Results 10Health News:Omnicell Announces Second Quarter 2009 Results 11Health News:Omnicell Announces Second Quarter 2009 Results 12Health News:Eastern Insurance Holdings, Inc. to Release 2nd Quarter 2009 Financial Results 2Health News:Eastern Insurance Holdings, Inc. to Release 2nd Quarter 2009 Financial Results 3Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 2Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 3Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 4Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 5Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 6Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 7Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 8Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 9Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 10Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 11Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 12Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 13Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 14Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 4Health News:Bone from blood: Circulating cells form bone outside the normal skeleton, Penn study finds 2Health News:Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock 2Health News:Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock 3
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
... represents the latest breakthrough in visual ... the Humphrey Matrix will help you ... and assess treatment alternatives. Enhanced patient ... complete long-term glaucoma care for your ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
... and disposable lens convenience for those with ... want crisp, clear vision with the convenience ... Vertex Toric lenses are manufactured using our ... a perfect edge on every lens. This ...
Medicine Products: